DNA methylation inhibitors in cancer: Recent and future approaches

Biochimie

Volumn 94, Issue 11, 2012, Pages 2280-2296

  Gros, Christina ^a   Fahy, Jacques ^a   Halby, Ludovic ^a   Dufau, Isabelle ^a   Erdmann, Alexandre ^a   Gregoire, Jean Marc ^a   Ausseil, Fréderic ^a   Vispé, Stéphane ^a   Arimondo, Paola B ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

DNA methylation; DNMT inhibitors; Epigenetics; Screening tests

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC AGENT; AZACITIDINE; CP 4200; CURCUMIN; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; DNA METHYLTRANSFERASE INHIBITOR; EPIGALLOCATECHIN GALLATE; FLAVONOID; GENISTEIN; HYDRALAZINE; MG 98; N PHTHALOYLTRYPTOPHAN; NANAOMYCIN A; PROCAINAMIDE; PROCAINE; PSAMMAPLIN A; QUINOLINE DERIVATIVE; S 110; SGI 1027; SGI 110; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VALPROATE MAGNESIUM; ZEBULARINE;

ACUTE GRANULOCYTIC LEUKEMIA; AMINO TERMINAL SEQUENCE; ANTINEOPLASTIC ACTIVITY; CANCER CELL CULTURE; CANCER GENE THERAPY; CANCER INHIBITION; CARBOXY TERMINAL SEQUENCE; CATALYSIS; CELL ASSAY; DNA METHYLATION; DRUG CYTOTOXICITY; DRUG DETERMINATION; DRUG SCREENING; DRUG STRUCTURE; ENZYME ASSAY; GENE MUTATION; GENE SEQUENCE; HUMAN; HYPERTENSION; IC 50; LEUKEMIA; MELANOMA; MYELODYSPLASTIC SYNDROME; NONHUMAN; OVARY CANCER; PROSTATE CANCER; PROTEIN DOMAIN; PROTEIN FUNCTION; REVIEW; RNA INTERFERENCE; SOLID TUMOR; TRANSCRIPTION REGULATION;

ANIMALS; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; ENZYME INHIBITORS; HUMANS; NEOPLASMS;

EID: 84867395940     PISSN: 03009084     EISSN: 61831638     Source Type: Journal    
DOI: 10.1016/j.biochi.2012.07.025     Document Type: Review

References (225)

1. A. Bird Perceptions of epigenetics Nature 447 2007 396 398
2. W. Reik Stability and flexibility of epigenetic gene regulation in mammalian development Nature 447 2007 425 432
3. C.H. Waddington The epigenotype Endeavour 1 1942 18 20
4. S.L. Berger, T. Kouzarides, R. Shiekhattar, and A. Shilatifard An operational definition of epigenetics Genes Dev. 23 2009 781 783
5. K. Luger, A.W. Mader, R.K. Richmond, D.F. Sargent, and T.J. Richmond Crystal structure of the nucleosome core particle at 2.8 A resolution Nature 389 1997 251 260
6. R. Margueron, and D. Reinberg Chromatin structure and the inheritance of epigenetic information Nat. Rev. Genet. 11 2010 285 296
7. M.S. Cosgrove, and C. Wolberger How does the histone code work? Biochem. Cell Biol. 83 2005 468 476
8. T. Kouzarides Chromatin modifications and their function Cell 128 2007 693 705
9. J. Wu, and M. Grunstein 25 Years after the nucleosome model: chromatin modifications Trends Biochem. Sci. 25 2000 619 623
10. P.V. Licciardi, F.A. Kwa, K. Ververis, C.N. Di, A. Balcerczyk, M.L. Tang, A. El-Osta, and T. Karagiannis Influence of natural and synthetic histone deacetylase inhibitors on chromatin Antioxid. Redox Signal. 2012
11. M. Grunstein Histone acetylation in chromatin structure and transcription Nature 389 1997 349 352
12. P.A. Marks, V.M. Richon, and R.A. Rifkind Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells J. Natl. Cancer Inst. 92 2000 1210 1216
13. C. Mercurio, S. Minucci, and P.G. Pelicci Histone deacetylases and epigenetic therapies of hematological malignancies Pharmacol. Res. 62 2010 18 34
14. J.E. Bolden, M.J. Peart, and R.W. Johnstone Anticancer activities of histone deacetylase inhibitors Nat. Rev. Drug Discov. 5 2006 769 784
15. K.D. Robertson, and P.A. Jones DNA methylation: past, present and future directions Carcinogenesis 21 2000 461 467
16. Y. Wang, and F.C. Leung An evaluation of new criteria for CpG islands in the human genome as gene markers Bioinformatics 20 2004 1170 1177
17. T.H. Bestor The DNA methyltransferases of mammals Hum. Mol. Genet. 9 2000 2395 2402
18. A. Doi, I.H. Park, B. Wen, P. Murakami, M.J. Aryee, R. Irizarry, B. Herb, C. Ladd-Acosta, J. Rho, S. Loewer, J. Miller, T. Schlaeger, G.Q. Daley, and A.P. Feinberg Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts Nat. Genet. 41 2009 1350 1353
19. R.A. Irizarry, C. Ladd-Acosta, B. Wen, Z. Wu, C. Montano, P. Onyango, H. Cui, K. Gabo, M. Rongione, M. Webster, H. Ji, J.B. Potash, S. Sabunciyan, and A.P. Feinberg The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores Nat. Genet. 41 2009 178 186
20. G.C. Prendergast, and E.B. Ziff Methylation-sensitive sequence-specific DNA binding by the c-Myc basic region Science 251 1991 186 189
21. F. Watt, and P.L. Molloy Cytosine methylation prevents binding to DNA of a HeLa cell transcription factor required for optimal expression of the adenovirus major late promoter Genes Dev. 2 1988 1136 1143
22. P.L. Jones, G.J. Veenstra, P.A. Wade, D. Vermaak, S.U. Kass, N. Landsberger, J. Strouboulis, and A.P. Wolffe Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription Nat. Genet. 19 1998 187 191
23. X. Nan, H.H. Ng, C.A. Johnson, C.D. Laherty, B.M. Turner, R.N. Eisenman, and A. Bird Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex Nature 393 1998 386 389
24. M. Esteller Epigenetics in cancer N. Engl. J. Med. 358 2008 1148 1159
25. A.P. Feinberg Phenotypic plasticity and the epigenetics of human disease Nature 447 2007 433 440
26. A.P. Feinberg, R. Ohlsson, and S. Henikoff The epigenetic progenitor origin of human cancer Nat. Rev. Genet. 7 2006 21 33
27. E. Prokhortchouk, and P.A. Defossez The cell biology of DNA methylation in mammals Biochim. Biophys. Acta 1783 2008 2167 2173
28. S. Sharma, T.K. Kelly, and P.A. Jones Epigenetics in cancer Carcinogenesis 31 2010 27 36
29. M. Szyf Epigenetics, DNA methylation, and chromatin modifying drugs Annu. Rev. Pharmacol. Toxicol. 49 2009 243 263
30. S. Ramchandani, S.K. Bhattacharya, N. Cervoni, and M. Szyf DNA methylation is a reversible biological signal Proc. Natl. Acad. Sci. U. S. A. 96 1999 6107 6112
31. M. Daskalakis, T.T. Nguyen, C. Nguyen, P. Guldberg, G. Kohler, P. Wijermans, P.A. Jones, and M. Lubbert Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2′- deoxycytidine (decitabine) treatment Blood 100 2002 2957 2964
32. J.P. Issa, G. Garcia-Manero, F.J. Giles, R. Mannari, D. Thomas, S. Faderl, E. Bayar, J. Lyons, C.S. Rosenfeld, J. Cortes, and H.M. Kantarjian Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies Blood 103 2004 1635 1640
33. S.D. Gore, S. Baylin, E. Sugar, H. Carraway, C.B. Miller, M. Carducci, M. Grever, O. Galm, T. Dauses, J.E. Karp, M.A. Rudek, M. Zhao, B.D. Smith, J. Manning, A. Jiemjit, G. Dover, A. Mays, J. Zwiebel, A. Murgo, L.J. Weng, and J.G. Herman Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms Cancer Res. 66 2006 6361 6369
34. C. Flotho, R. Claus, C. Batz, M. Schneider, I. Sandrock, S. Ihde, C. Plass, C.M. Niemeyer, and M. Lubbert The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells Leukemia 23 2009 1019 1028
35. T. Shimamoto, J.H. Ohyashiki, and K. Ohyashiki Methylation of p15(INK4b) and E-cadherin genes is independently correlated with poor prognosis in acute myeloid leukemia Leuk. Res. 29 2005 653 659
36. P.W. Wijermans, M. Lubbert, G. Verhoef, V. Klimek, and A. Bosly An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2′-deoxycytidine (decitabine) in 177 patients Ann. Hematol. 84 Suppl. 1 2005 9 17
37. P. Wijermans, M. Lubbert, G. Verhoef, A. Bosly, C. Ravoet, M. Andre, and A. Ferrant Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients J. Clin. Oncol. 18 2000 956 962
38. M. Schaefer, and F. Lyko Solving the Dnmt2 enigma Chromosoma 119 2010 35 40
39. J.E. Squires, H.R. Patel, M. Nousch, T. Sibbritt, D.T. Humphreys, B.J. Parker, C.M. Suter, and T. Preiss Widespread occurrence of 5-methylcytosine in human coding and non-coding RNA Nucleic Acids Res. 2012
40. B.H. Ramsahoye, D. Biniszkiewicz, F. Lyko, V. Clark, A.P. Bird, and R. Jaenisch Non-CpG methylation is prevalent in embryonic stem cells and may be mediated by DNA methyltransferase 3a Proc. Natl. Acad. Sci. U. S. A. 97 2000 5237 5242
41. S. Kouidou, T. Agidou, A. Kyrkou, A. Andreou, T. Katopodi, E. Georgiou, D. Krikelis, A. Dimitriadou, P. Spanos, C. Tsilikas, H. Destouni, and G. Tzimagiorgis Non-CpG cytosine methylation of p53 exon 5 in non-small cell lung carcinoma Lung Cancer 50 2005 299 307
42. J. Yan, J.R. Zierath, and R. Barres Evidence for non-CpG methylation in mammals Exp. Cell Res. 317 2011 2555 2561
43. X. Cheng, and R.M. Blumenthal Coordinated chromatin control: structural and functional linkage of DNA and histone methylation Biochemistry 49 2010 2999 3008
44. R.Z. Jurkowska, T.P. Jurkowski, and A. Jeltsch Structure and function of mammalian DNA methyltransferases ChemBioChem 12 2011 206 222
45. Z.M. Svedruzic Mammalian cytosine DNA methyltransferase Dnmt1: enzymatic mechanism, novel mechanism-based inhibitors, and RNA-directed DNA methylation Curr. Med. Chem. 15 2008 92 106
46. R. Lauster, T.A. Trautner, and M. Noyer-Weidner Cytosine-specific type II DNA methyltransferases. A conserved enzyme core with variable target-recognizing domains J. Mol. Biol. 206 1989 305 312
47. K.D. Robertson DNA methylation, methyltransferases, and cancer Oncogene 20 2001 3139 3155
48. T.H. Bestor, and G.L. Verdine DNA methyltransferases Curr. Opin. Cell Biol. 6 1994 380 389
49. T. Bestor, A. Laudano, R. Mattaliano, and V. Ingram Cloning and sequencing of a cDNA encoding DNA methyltransferase of mouse cells. The carboxyl-terminal domain of the mammalian enzymes is related to bacterial restriction methyltransferases J. Mol. Biol. 203 1988 971 983
50. T.H. Bestor Cloning of a mammalian DNA methyltransferase Gene 74 1988 9 12
51. K.D. Robertson, E. Uzvolgyi, G. Liang, C. Talmadge, J. Sumegi, F.A. Gonzales, and P.A. Jones The human DNA methyltransferases (DNMTs) 1, 3a and 3b: coordinate mRNA expression in normal tissues and overexpression in tumors Nucleic Acids Res. 27 1999 2291 2298
52. C. Mertineit, J.A. Yoder, T. Taketo, D.W. Laird, J.M. Trasler, and T.H. Bestor Sex-specific exons control DNA methyltransferase in mammalian germ cells Development 125 1998 889 897
53. S. Pradhan, D. Talbot, M. Sha, J. Benner, L. Hornstra, E. Li, R. Jaenisch, and R.J. Roberts Baculovirus-mediated expression and characterization of the full-length murine DNA methyltransferase Nucleic Acids Res. 25 1997 4666 4673
54. S. Pradhan, A. Bacolla, R.D. Wells, and R.J. Roberts Recombinant human DNA (cytosine-5) methyltransferase. I. Expression, purification, and comparison of de novo and maintenance methylation J. Biol. Chem. 274 1999 33002 33010
55. E. Li, T.H. Bestor, and R. Jaenisch Targeted mutation of the DNA methyltransferase gene results in embryonic lethality Cell 69 1992 915 926
56. S. Takashima, M. Takehashi, J. Lee, S. Chuma, M. Okano, K. Hata, I. Suetake, N. Nakatsuji, H. Miyoshi, S. Tajima, Y. Tanaka, S. Toyokuni, H. Sasaki, M. Kanatsu-Shinohara, and T. Shinohara Abnormal DNA methyltransferase expression in mouse germline stem cells results in spermatogenic defects Biol. Reprod. 81 2009 155 164
57. T. Chen, S. Hevi, F. Gay, N. Tsujimoto, T. He, B. Zhang, Y. Ueda, and E. Li Complete inactivation of DNMT1 leads to mitotic catastrophe in human cancer cells Nat. Genet. 39 2007 391 396
58. F. Gaudet, J.G. Hodgson, A. Eden, L. Jackson-Grusby, J. Dausman, J.W. Gray, H. Leonhardt, and R. Jaenisch Induction of tumors in mice by genomic hypomethylation Science 300 2003 489 492
59. A. Eden, F. Gaudet, A. Waghmare, and R. Jaenisch Chromosomal instability and tumors promoted by DNA hypomethylation Science 300 2003 455
60. F. Chik, and M. Szyf Effects of specific DNMT gene depletion on cancer cell transformation and breast cancer cell invasion; toward selective DNMT inhibitors Carcinogenesis 32 2011 224 232
61. J. Sharif, and H. Koseki Recruitment of Dnmt1 roles of the SRA protein Np95 (Uhrf1) and other factors Prog. Mol. Biol. Transl. Sci. 101 2011 289 310
62. T. Iida, I. Suetake, S. Tajima, H. Morioka, S. Ohta, C. Obuse, and T. Tsurimoto PCNA clamp facilitates action of DNA cytosine methyltransferase 1 on hemimethylated DNA Genes Cells 7 2002 997 1007
63. J. Lan, S. Hua, X. He, and Y. Zhang DNA methyltransferases and methyl-binding proteins of mammals Acta Biochim. Biophys. Sin. (Shanghai) 42 2010 243 252
64. A.D. Riggs, Z. Xiong, L. Wang, and J.M. LeBon Methylation dynamics, epigenetic fidelity and X chromosome structure Novartis. Found. Symp. 214 1998 214 225
65. P.A. Jones, and G. Liang Rethinking how DNA methylation patterns are maintained Nat. Rev. Genet. 10 2009 805 811
66. R.S. Hansen, C. Wijmenga, P. Luo, A.M. Stanek, T.K. Canfield, C.M. Weemaes, and S.M. Gartler The DNMT3B DNA methyltransferase gene is mutated in the ICF immunodeficiency syndrome Proc. Natl. Acad. Sci. U. S. A. 96 1999 14412 14417
67. M. Okano, S. Xie, and E. Li Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases Nat. Genet. 19 1998 219 220
68. R. Deplus, C. Brenner, W.A. Burgers, P. Putmans, T. Kouzarides, L.Y. de, and F. Fuks Dnmt3L is a transcriptional repressor that recruits histone deacetylase Nucleic Acids Res. 30 2002 3831 3838
69. J.B. Margot, A.E. Ehrenhofer-Murray, and H. Leonhardt Interactions within the mammalian DNA methyltransferase family BMC Mol. Biol. 4 2003 7
70. D. Jia, R.Z. Jurkowska, X. Zhang, A. Jeltsch, and X. Cheng Structure of Dnmt3a bound to Dnmt3L suggests a model for de novo DNA methylation Nature 449 2007 248 251
71. R.Z. Jurkowska, N. Anspach, C. Urbanke, D. Jia, R. Reinhardt, W. Nellen, X. Cheng, and A. Jeltsch Formation of nucleoprotein filaments by mammalian DNA methyltransferase Dnmt3a in complex with regulator Dnmt3L Nucleic Acids Res. 36 2008 6656 6663
72. Y.Z. Ge, M.T. Pu, H. Gowher, H.P. Wu, J.P. Ding, A. Jeltsch, and G.L. Xu Chromatin targeting of de novo DNA methyltransferases by the PWWP domain J. Biol. Chem. 279 2004 25447 25454
73. A. Hermann, H. Gowher, and A. Jeltsch Biochemistry and biology of mammalian DNA methyltransferases Cell. Mol. Life Sci. 61 2004 2571 2587
74. J. Espada, and M. Esteller DNA methylation and the functional organization of the nuclear compartment Semin. Cell Dev. Biol. 21 2010 238 246
75. M. Fatemi, A. Hermann, H. Gowher, and A. Jeltsch Dnmt3a and Dnmt1 functionally cooperate during de novo methylation of DNA Eur. J. Biochem. 269 2002 4981 4984
76. G.D. Kim, J. Ni, N. Kelesoglu, R.J. Roberts, and S. Pradhan Co-operation and communication between the human maintenance and de novo DNA (cytosine-5) methyltransferases EMBO J. 21 2002 4183 4195
77. F. Xu, C. Mao, Y. Ding, C. Rui, L. Wu, A. Shi, H. Zhang, L. Zhang, and Z. Xu Molecular and enzymatic profiles of mammalian DNA methyltransferases: structures and targets for drugs Curr. Med. Chem. 17 2010 4052 4071
78. E.L. Walton, C. Francastel, and G. Velasco Maintenance of DNA methylation: Dnmt3b joins the dance Epigenetics 6 2011
79. R. Goyal, R. Reinhardt, and A. Jeltsch Accuracy of DNA methylation pattern preservation by the Dnmt1 methyltransferase Nucleic Acids Res. 34 2006 1182 1188
80. I. Rhee, K.E. Bachman, B.H. Park, K.W. Jair, R.W. Yen, K.E. Schuebel, H. Cui, A.P. Feinberg, C. Lengauer, K.W. Kinzler, S.B. Baylin, and B. Vogelstein DNMT1 and DNMT3b cooperate to silence genes in human cancer cells Nature 416 2002 552 556
81. A. Mai, and L. Altucci Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead Int. J. Biochem. Cell Biol. 41 2009 199 213
82. T.A. Paul, J. Bies, D. Small, and L. Wolff Signatures of polycomb repression and reduced H3K4 trimethylation are associated with p15INK4b DNA methylation in AML Blood 115 2010 3098 3108
83. T. Kouzarides Histone methylation in transcriptional control Curr. Opin. Genet. Dev. 12 2002 198 209
84. K. Marushige Activation of chromatin by acetylation of histone side chains Proc. Natl. Acad. Sci. U. S. A. 73 1976 3937 3941
85. W.S. Xu, R.B. Parmigiani, and P.A. Marks Histone deacetylase inhibitors: molecular mechanisms of action Oncogene 26 2007 5541 5552
86. K.D. Robertson DNA methylation and chromatin - unraveling the tangled web Oncogene 21 2002 5361 5379
87. J. Espada, and M. Esteller Epigenetic control of nuclear architecture Cell. Mol. Life Sci. 64 2007 449 457
88. T. Clouaire, and I. Stancheva Methyl-CpG binding proteins: specialized transcriptional repressors or structural components of chromatin? Cell. Mol. Life Sci. 65 2008 1509 1522
89. O. Bogdanovic, and G.J. Veenstra DNA methylation and methyl-CpG binding proteins: developmental requirements and function Chromosoma 118 2009 549 565
90. A.P. Feinberg Epigenetics at the epicenter of modern medicine J. Am. Med. Assoc. 299 2008 1345 1350
91. I.A. Qureshi, and M.F. Mehler Advances in epigenetics and epigenomics for neurodegenerative diseases Curr. Neurol. Neurosci. Rep. 11 2011 464 473
92. P.A. Jones, and S.B. Baylin The epigenomics of cancer Cell 128 2007 683 692
93. J.G. Herman, and S.B. Baylin Gene silencing in cancer in association with promoter hypermethylation N. Engl. J. Med. 349 2003 2042 2054
94. A. Fuso, V. Nicolia, R.A. Cavallaro, and S. Scarpa DNA methylase and demethylase activities are modulated by one-carbon metabolism in Alzheimer's disease models J. Nutr. Biochem. 22 2011 242 251
95. F. Higuchi, S. Uchida, H. Yamagata, K. Otsuki, T. Hobara, N. Abe, T. Shibata, and Y. Watanabe State-dependent changes in the expression of DNA methyltransferases in mood disorder patients J. Psychiatr. Res. 45 2011 1295 1300
96. C. Lopez-Pedrera, C. Perez-Sanchez, M. Ramos-Casals, M. Santos-Gonzalez, A. Rodriguez-Ariza, and M.J. Cuadrado Cardiovascular risk in systemic autoimmune diseases: epigenetic mechanisms of immune regulatory functions Clin. Dev. Immunol. 2012 2012 974648
97. S. Sacconi, P. Camano, J.C. de Greef, R.J. Lemmers, L. Salviati, P. Boileau, A.A. Lopez de Munain, S.M. van der Maarel, and C. Desnuelle Patients with a phenotype consistent with facioscapulohumeral muscular dystrophy display genetic and epigenetic heterogeneity J. Med. Genet. 2011
98. J.M. Statland, and R. Tawil Facioscapulohumeral muscular dystrophy: molecular pathological advances and future directions Curr. Opin. Neurol. 24 2011 423 428
99. E.R. Nimmo, J.G. Prendergast, M.C. Aldhous, N.A. Kennedy, P. Henderson, H.E. Drummond, B.H. Ramsahoye, D.C. Wilson, C.A. Semple, and J. Satsangi Genome-wide methylation profiling in Crohn's disease identifies altered epigenetic regulation of key host defense mechanisms including the Th17 pathway Inflamm. Bowel Dis. 2011
100. J. Bressler, L.C. Shimmin, E. Boerwinkle, and J.E. Hixson Global DNA methylation and risk of subclinical atherosclerosis in young adults: the pathobiological determinants of atherosclerosis in youth (PDAY) study Atherosclerosis 2011
101. J. Rodriguez, J. Frigola, E. Vendrell, R.A. Risques, M.F. Fraga, C. Morales, V. Moreno, M. Esteller, G. Capella, M. Ribas, and M.A. Peinado Chromosomal instability correlates with genome-wide DNA demethylation in human primary colorectal cancers Cancer Res. 66 2006 8462 9468
102. K. Balassiano, S. Lima, M. Jenab, K. Overvad, A. Tjonneland, M.C. Boutron-Ruault, F. Clavel- Chapelon, F. Canzian, R. Kaaks, H. Boeing, K. Meidtner, A. Trichopoulou, P. Laglou, P. Vineis, S. Panico, D. Palli, S. Grioni, R. Tumino, E. Lund, H.B. Bueno-de-Mesquita, M.E. Numans, P.H. Peeters, Q.J. Ramon, M.J. Sanchez, C. Navarro, E. Ardanaz, M. Dorronsoro, G. Hallmans, R. Stenling, R. Ehrnstrom, S. Regner, N.E. Allen, R.C. Travis, K.T. Khaw, G.J. Offerhaus, N. Sala, E. Riboli, P. Hainaut, J.Y. Scoazec, B.S. Sylla, C.A. Gonzalez, and Z. Herceg Aberrant DNA methylation of cancer-associated genes in gastric cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST) Cancer Lett. 311 2011 85 95
103. C.S. Chim, A.S. Wong, and Y.L. Kwong Epigenetic inactivation of INK4/CDK/RB cell cycle pathway in acute leukemias Ann. Hematol. 82 2003 738 742
104. S. Ropero, F. Setien, J. Espada, M.F. Fraga, M. Herranz, J. Asp, M.S. Benassi, A. Franchi, A. Patino, L.S. Ward, J. Bovee, J.C. Cigudosa, W. Wim, and M. Esteller Epigenetic loss of the familial tumor-suppressor gene exostosin-1 (EXT1) disrupts heparan sulfate synthesis in cancer cells Hum. Mol. Genet. 13 2004 2753 2765
105. N.J. Farinha, S. Shaker, M. Lemaire, L. Momparler, M. Bernstein, and R.L. Momparler Activation of expression of p15, p73 and E-cadherin in leukemic cells by different concentrations of 5-aza-2′-deoxycytidine (decitabine) Anticancer Res. 24 2004 75 78
106. A. Sowinska, and P.P. Jagodzinski RNA interference-mediated knockdown of DNMT1 and DNMT3B induces CXCL12 expression in MCF-7 breast cancer and AsPC1 pancreatic carcinoma cell lines Cancer Lett. 255 2007 153 159
107. Y.W. Leu, F. Rahmatpanah, H. Shi, S.H. Wei, J.C. Liu, P.S. Yan, and T.H.-M. Huang Double RNA interference of DNMT3b and DNMT1 enhances DNA demethylation and gene reactivation Cancer Res. 63 2003 6110 6115
108. G. Foltz, J.-G. Yoon, H. Lee, T.C. Ryken, Z. Sibenaller, M. Ehrich, L. Hood, and A. Madan DNA methyltransferase-mediated transcriptional silencing in malignant glioma: a combined whole-genome microarray and promoter array analysis Oncogene 28 2009 2667 2677
109. Y. Jung, J. Park, T. Kim, J.H. Park, H.S. Jong, S.A. Im, K. Robertson, Y.J. Bang, and T.Y. Kim Potential advantages of DNA methyltransferase 1 (DNMT1)-targeted inhibition for cancer therapy J. Mol. Med. 85 2007 1137 1148
110. E.S. Kassis, M. Zhao, J.A. Hong, G.A. Chen, D.M. Nguyen, and D.S. Schrump Depletion of DNA methyltransferase 1 and/or DNA methyltransferase 3b mediates growth arrest and apoptosis in lung and esophageal cancer and malignant pleural mesothelioma cells J. Thorac. Cardiovasc. Surg. 131 2006 298 306
111. N. Oridate, and R. Lotan Suppression of DNA methyltransferase 1 levels in head and neck squamous carcinoma cells using small interfering RNA results in growth inhibition and increase in Cdk inhibitor p21 Int. J. Oncol. 26 2005 757 761
112. M. Suzuki, N. Sunaga, D.S. Shames, S. Toyooka, A.F. Gazdar, and J.D. Minna RNA interference-mediated knockdown of DNA methyltransferase 1 leads to promoter demethylation and gene re-expression in human lung and breast cancer cells Cancer Res. 64 2004 3137 3143
113. Y. Zhang, F.Q. Chen, Y.H. Sun, S.Y. Zhou, T.Y. Li, and R. Chen Effects of DNMT1 silencing on malignant phenotype and methylated gene expression in cervical cancer cells J. Exp. Clin. Cancer Res. 30 2011 98
114. K. Minami, T. Chano, T. Kawakami, H. Ushida, R. Kushima, H. Okabe, Y. Okada, and K. Okamoto DNMT3L is a novel marker and is essential for the growth of human embryonal carcinoma Clin. Cancer Res. 16 2010 2751 2759
115. T.J. Ley, L. Ding, M.J. Walter, M.D. McLellan, T. Lamprecht, D.E. Larson, C. Kandoth, J.E. Payton, J. Baty, J. Welch, C.C. Harris, C.F. Lichti, R.R. Townsend, R.S. Fulton, D.J. Dooling, D.C. Koboldt, H. Schmidt, Q. Zhang, J.R. Osborne, L. Lin, M. O'Laughlin, J.F. McMichael, K.D. Delehaunty, S.D. McGrath, L.A. Fulton, V.J. Magrini, T.L. Vickery, J. Hundal, L.L. Cook, J.J. Conyers, G.W. Swift, J.P. Reed, P.A. Alldredge, T. Wylie, J. Walker, J. Kalicki, M.A. Watson, S. Heath, W.D. Shannon, N. Varghese, R. Nagarajan, P. Westervelt, M.H. Tomasson, D.C. Link, T.A. Graubert, J.F. DiPersio, E.R. Mardis, and R.K. Wilson DNMT3A mutations in acute myeloid leukemia N. Engl. J. Med. 363 2010 2424 2433
116. M.J. Walter, L. Ding, D. Shen, J. Shao, M. Grillot, M. McLellan, R. Fulton, H. Schmidt, J. Kalicki-Veizer, M. O'Laughlin, C. Kandoth, J. Baty, P. Westervelt, J.F. DiPersio, E.R. Mardis, R.K. Wilson, T.J. Ley, and T.A. Graubert Recurrent DNMT3A mutations in patients with myelodysplastic syndromes Leukemia 25 2011 1153 1158
117. Q. Gao, E.J. Steine, M.I. Barrasa, D. Hockemeyer, M. Pawlak, D. Fu, S. Reddy, G.W. Bell, and R. Jaenisch Deletion of the de novo DNA methyltransferase Dnmt3a promotes lung tumor progression Proc. Natl. Acad. Sci. U. S. A. 108 2011 18061 18066
118. R.A. Hlady, S. Novakova, J. Opavska, D. Klinkebiel, S.L. Peters, J. Bies, J. Hannah, J. Iqbal, K.M. Anderson, H.M. Siebler, L.M. Smith, T.C. Greiner, D. Bastola, S. Joshi, O. Lockridge, M.A. Simpson, D.W. Felsher, K.U. Wagner, W.C. Chan, J.K. Christman, and R. Opavsky Loss of Dnmt3b function upregulates the tumor modifier Ment and accelerates mouse lymphomagenesis J. Clin. Invest. 122 2012 163 177
119. Y. Kobayashi, D.M. Absher, Z.G. Gulzar, S.R. Young, J.K. McKenney, D.M. Peehl, J.D. Brooks, R.M. Myers, and G. Sherlock DNA methylation profiling reveals novel biomarkers and important roles for DNA methyltransferases in prostate cancer Genome Res. 21 2011 1017 1027
120. Y. Qu, G. Mu, Y. Wu, X. Dai, F. Zhou, X. Xu, Y. Wang, and F. Wei Overexpression of DNA methyltransferases 1, 3a, and 3b significantly correlates with retinoblastoma tumorigenesis Am. J. Clin. Pathol. 134 2010 826 834
121. G. Rajendran, K. Shanmuganandam, A. Bendre, D. Muzumdar, A. Goel, and A. Shiras Epigenetic regulation of DNA methyltransferases: DNMT1 and DNMT3B in gliomas J. Neurooncol. 104 2011 483 494
122. J. Yang, X. Wei, Q. Wu, Z. Xu, D. Gu, Y. Jin, Y. Shen, H. Huang, H. Fan, and J. Chen Clinical significance of the expression of DNA methyltransferase proteins in gastric cancer Mol. Med. Rep. 4 2011 1139 1143
123. K. Amara, S. Ziadi, M. Hachana, N. Soltani, S. Korbi, and M. Trimeche DNA methyltransferase DNMT3b protein overexpression as a prognostic factor in patients with diffuse large B-cell lymphomas Cancer Sci. 101 2010 1722 1730
124. H. Fan, L. Chen, F. Zhang, Y. Quan, X. Su, X. Qiu, Z. Zhao, K.L. Kong, S. Dong, Y. Song, T.H.M. Chan, and X.Y. Guan MTSS1, a novel target of DNA methyltransferase 3B, functions as a tumor suppressor in hepatocellular carcinoma Oncogene 2011
125. A.E. Ibrahim, M.J. Arends, A.L. Silva, A.H. Wyllie, L. Greger, Y. Ito, S.L. Vowler, T.H. Huang, S. Tavare, A. Murrell, and J.D. Brenton Sequential DNA methylation changes are associated with DNMT3B overexpression in colorectal neoplastic progression Gut 60 2011 499 508
126. S. Mizuno, T. Chijiwa, T. Okamura, K. Akashi, Y. Fukumaki, Y. Niho, and H. Sasaki Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia Blood 97 2001 1172 1179
127. S. Klimasauskas, S. Kumar, R.J. Roberts, and X. Cheng HhaI methyltransferase flips its target base out of the DNA helix Cell 76 1994 357 369
128. Z.M. Svedruzic, and N.O. Reich Mechanism of allosteric regulation of Dnmt1's processivity Biochemistry 44 2005 14977 14988
129. G. Ibanez, J.L. McBean, Y.M. Astudillo, and M. Luo An enzyme-coupled ultrasensitive luminescence assay for protein methyltransferases Anal. Biochem. 401 2010 203 210
130. I. Hemeon, J.A. Gutierrez, M.C. Ho, and V.L. Schramm Characterizing DNA methyltransferases with an ultrasensitive luciferase-linked continuous assay Anal. Chem. 83 2011 4996 5004
131. T.L. Graves, Y. Zhang, and J.E. Scott A universal competitive fluorescence polarization activity assay for S-adenosylmethionine utilizing methyltransferases Anal. Biochem. 373 2008 296 306
132. N. Rouleau, L. Silva, I. Ryabov, P. Roby, A. Marcil, Development of a Non-Radioactive, No-Wash Biochemical Assay for High-Throughput Screening of Small Molecule Modulators of DNA Methyltransferases, Proceedings of the SBS Conference (2011).
133. J.H. Zhang, T.D. Chung, and K.R. Oldenburg A simple statistical parameter for use in evaluation and validation of high throughput screening assays J. Biomol. Screen. 4 1999 67 73
134. A. Ceccaldi, A. Rajavelu, C. Champion, C. Rampon, R. Jurkowska, G. Jankevicius, C. Senamaud-Beaufort, L. Ponger, N. Gagey, H.D. Ali, J. Tost, S. Vriz, S. Ros, D. Dauzonne, A. Jeltsch, D. Guianvarc'h, and P.B. Arimondo C5-DNA methyltransferase inhibitors: from screening to effects on zebrafish embryo development ChemBioChem 12 2011 1337 1345
135. Y.H. Woo, P.T. Rajagopalan, and S.J. Benkovic A nonradioactive DNA methyltransferase assay adaptable to high-throughput screening Anal. Biochem. 340 2005 336 340
136. Y. Ye, and J.T. Stivers Fluorescence-based high-throughput assay for human DNA (cytosine-5)-methyltransferase 1 Anal. Biochem. 401 2010 168 172
137. N. Mashhoon, C. Pruss, M. Carroll, P.H. Johnson, and N.O. Reich Selective inhibitors of bacterial DNA adenine methyltransferases J. Biomol. Screen. 11 2006 497 510
138. J.L. Medina-Franco, F. Lopez-Vallejo, D. Kuck, and F. Lyko Natural products as DNA methyltransferase inhibitors: a computer-aided discovery approach Mol. Divers. 15 2011 293 304
139. M. Roth, and A. Jeltsch Biotin-avidin microplate assay for the quantitative analysis of enzymatic methylation of DNA by DNA methyltransferases Biol. Chem. 381 2000 269 272
140. R.L. Johnson, W. Huang, A. Jadhav, C.P. Austin, J. Inglese, and E.D. Martinez A quantitative high-throughput screen identifies potential epigenetic modulators of gene expression Anal. Biochem. 375 2008 237 248
141. S.H. Hsiao, K.D. Lee, C.C. Hsu, M.J. Tseng, V.X. Jin, W.S. Sun, Y.C. Hung, K.T. Yeh, P.S. Yan, Y.Y. Lai, H.S. Sun, Y.J. Lu, Y.S. Chang, S.J. Tsai, T.H. Huang, and Y.W. Leu DNA methylation of the Trip10 promoter accelerates mesenchymal stem cell lineage determination Biochem. Biophys. Res. Commun. 400 2010 305 312
142. Y.S. Lin, A.Y. Shaw, S.G. Wang, C.C. Hsu, I.W. Teng, M.J. Tseng, T.H. Huang, C.S. Chen, Y.W. Leu, and S.H. Hsiao Identification of novel DNA methylation inhibitors via a two-component reporter gene system J. Biomed. Sci. 18 2011 3 10
143. C.B. Yoo, and P.A. Jones Epigenetic therapy of cancer: past, present and future Nat. Rev. Drug Discov. 5 2006 37 50
144. X. Yang, F. Lay, H. Han, and P.A. Jones Targeting DNA methylation for epigenetic therapy Trends Pharmacol. Sci. 31 2010 536 546
145. F. Sorm, and J. Vesely Effect of 5-aza-2′-deoxycytidine against leukemic and hemopoietic tissues in AKR mice Neoplasma 15 1968 339 343
146. P.G. Constantinides, P.A. Jones, and W. Gevers Functional striated muscle cells from non-myoblast precursors following 5-azacytidine treatment Nature 267 1977 364 366
147. P.G. Constantinides, S.M. Taylor, and P.A. Jones Phenotypic conversion of cultured mouse embryo cells by aza pyrimidine nucleosides Dev. Biol. 66 1978 57 71
148. P.A. Jones, and S.M. Taylor Cellular differentiation, cytidine analogs and DNA methylation Cell 20 1980 85 93
149. R.L. Momparler Pharmacology of 5-Aza-2′-deoxycytidine (decitabine) Semin. Hematol. 42 2005 S9 16
150. D.V. Santi, A. Norment, and C.E. Garrett Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine Proc. Natl. Acad. Sci. U. S. A. 81 1984 6993 6997
151. K. Ghoshal, J. Datta, S. Majumder, S. Bai, H. Kutay, T. Motiwala, and S.T. Jacob 5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal Mol. Cell. Biol. 25 2005 4727 4741
152. H.K. Kuo, J.D. Griffith, and K.N. Kreuzer 5-Azacytidine induced methyltransferase-DNA adducts block DNA replication in vivo Cancer Res. 67 2007 8248 8254
153. T. Qin, J. Jelinek, J. Si, J. Shu, and J.P. Issa Mechanisms of resistance to 5-aza-2′-deoxycytidine in human cancer cell lines Blood 113 2009 659 667
154. P.W. Hollenbach, A.N. Nguyen, H. Brady, M. Williams, Y. Ning, N. Richard, L. Krushel, S.L. Aukerman, C. Heise, and K.J. MacBeth A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines PLoS One 5 2010 e9001
155. G.L. Gravina, C. Festuccia, F. Marampon, V.M. Popov, R.G. Pestell, B.M. Zani, and V. Tombolini Biological rationale for the use of DNA methyltransferase inhibitors as new strategy for modulation of tumor response to chemotherapy and radiation Mol. Cancer 9 2010 305
156. C. Champion, D. Guianvarc'h, C. Senamaud-Beaufort, R.Z. Jurkowska, A. Jeltsch, L. Ponger, P.B. Arimondo, and A.L. Guieysse-Peugeot Mechanistic insights on the inhibition of c5 DNA methyltransferases by zebularine PLoS One 5 2010 e12388
157. R.L. Piekarz, and S.E. Bates Epigenetic modifiers: basic understanding and clinical development Clin. Cancer Res. 15 2009 3918 3926
158. L.S. Kristensen, H.M. Nielsen, and L.L. Hansen Epigenetics and cancer treatment Eur. J. Pharmacol. 625 2009 131 142
159. R.A. Juergens, J. Wrangle, F.P. Vendetti, S.C. Murphy, M. Zhao, B. Coleman, R. Sebree, K. Rodgers, C.M. Hooker, N. Franco, B. Lee, S. Tsai, I.E. Delgado, M.A. Rudek, S.A. Belinsky, J.G. Herman, S.B. Baylin, M.V. Brock, and C.M. Rudin Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer Cancer Discov. 1 2011 598 607
160. B. Brueckner, M. Rius, M.R. Markelova, I. Fichtner, P.A. Hals, M.L. Sandvold, and F. Lyko Delivery of 5-azacytidine to human cancer cells by elaidic acid esterification increases therapeutic drug efficacy Mol. Cancer Ther. 9 2010 1256 1264
161. C.B. Yoo, S. Jeong, G. Egger, G. Liang, P. Phiasivongsa, C. Tang, S. Redkar, and P.A. Jones Delivery of 5-aza-2′-deoxycytidine to cells using oligodeoxynucleotides Cancer Res. 67 2007 6400 6408
162. J.C. Chuang, S.L. Warner, D. Vollmer, H. Vankayalapati, S. Redkar, D.J. Bearss, X. Qiu, C.B. Yoo, and P.A. Jones S110, a 5-Aza-2′-deoxycytidine- containing dinucleotide, is an effective DNA methylation inhibitor in vivo and can reduce tumor growth Mol. Cancer Ther. 9 2010 1443 1450
163. F. Galeotti, E. Barile, P. Curir, M. Dolci, and V. Lanzotti Flavonoids from carnation (Dianthus caryophyllus) and their antifungal activity Phytochem. Lett. 1 2008 44 48
164. C.S. Yang, X. Wang, G. Lu, and S.C. Picinich Cancer prevention by tea: animal studies, molecular mechanisms and human relevance Nat. Rev. Cancer 9 2009 429 439
165. B.N. Singh, S. Shankar, and R.K. Srivastava Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications Biochem. Pharmacol. 82 2011 1807 1821
166. N. Suh, and J.M. Pezzuto Strawberry fields forever? Cancer Prev. Res. (Phila) 5 2012 30 33
167. E.D. Walter Genistein (an isoflavone glucoside) and its aglucone, genistein, from soybeans J. Am. Chem. Soc. 63 1941 3273 3276
168. J.D. Biggers, and D.H. Curnow Oestrogenic activity of subterranean clover. I. The oestrogenic activity of genistein Biochem. J. 58 1954 278 282
169. S. Banerjee, Y. Li, Z. Wang, and F.H. Sarkar Multi-targeted therapy of cancer by genistein Cancer Lett. 269 2008 226 242
170. A. Rusin, Z. Krawczyk, G. Grynkiewicz, A. Gogler, J. Zawisza-Puchalka, and W. Szeja Synthetic derivatives of genistein, their properties and possible applications Acta Biochim. Pol 57 2010 23 34
171. S.J. Duthie Epigenetic modifications and human pathologies: cancer and CVD Proc. Nutr. Soc. 70 2011 47 56
172. M. Fang, D. Chen, and C.S. Yang Dietary polyphenols may affect DNA methylation J. Nutr. 137 2007 223S 228S
173. M.Z. Fang, D. Chen, Y. Sun, Z. Jin, J.K. Christman, and C.S. Yang Reversal of hypermethylation and reactivation of p16INK4a, RARbeta, and MGMT genes by genistein and other isoflavones from soy Clin. Cancer Res. 11 2005 7033 7041
174. Y. Li, and T.O. Tollefsbol Impact on DNA methylation in cancer prevention and therapy by bioactive dietary components Curr. Med. Chem. 17 2010 2141 2151
175. W.J. Lee, J.Y. Shim, and B.T. Zhu Mechanisms for the inhibition of DNA methyltransferases by tea catechins and bioflavonoids Mol. Pharmacol. 68 2005 1018 1030
176. J.C. Chuang, C.B. Yoo, J.M. Kwan, T.W. Li, G. Liang, A.S. Yang, and P.A. Jones Comparison of biological effects of non-nucleoside DNA methylation inhibitors versus 5-aza-2′-deoxycytidine Mol. Cancer Ther. 4 2005 1515 1520
177. C. Stresemann, B. Brueckner, T. Musch, H. Stopper, and F. Lyko Functional diversity of DNA methyltransferase inhibitors in human cancer cell lines Cancer Res. 66 2006 2794 2800
178. B. Brueckner, D. Kuck, and F. Lyko DNA methyltransferase inhibitors for cancer therapy Cancer J. 13 2007 17 22
179. P. Zambrano, B. Segura-Pacheco, E. Perez-Cardenas, L. Cetina, A. Revilla-Vazquez, L. Taja-Chayeb, A. Chavez-Blanco, E. Angeles, G. Cabrera, K. Sandoval, C. Trejo-Becerril, J. Chanona-Vilchis, and A. Duenas-Gonzalez A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes BMC Cancer 5 2005 44
180. M. Candelaria, D. Gallardo-Rincon, C. Arce, L. Cetina, J.L. Aguilar-Ponce, O. Arrieta, A. Gonzalez-Fierro, A. Chavez-Blanco, E. Cruz-Hernandez, M.F. Camargo, C. Trejo-Becerril, E. Perez-Cardenas, C. Perez-Plasencia, L. Taja-Chayeb, T. Wegman-Ostrosky, A. Revilla-Vazquez, and A. Duenas-Gonzalez A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors Ann. Oncol. 18 2007 1529 1538
181. M. Candelaria, A. Herrera, J. Labardini, A. Gonzalez-Fierro, C. Trejo-Becerril, L. Taja-Chayeb, E. Perez-Cardenas, E. Cruz-Hernandez, D. Arias-Bofill, S. Vidal, E. Cervera, and A. Duenas-Gonzalez Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial Ann. Hematol. 90 2011 379 387
182. E. Cornacchia, J. Golbus, J. Maybaum, J. Strahler, S. Hanash, and B. Richardson Hydralazine and procainamide inhibit T cell DNA methylation and induce autoreactivity J. Immunol. 140 1988 2197 2200
183. A. Villar-Garea, M.F. Fraga, J. Espada, and M. Esteller Procaine is a DNA-demethylating agent with growth-inhibitory effects in human cancer cells Cancer Res. 63 2003 4984 4989
184. N. Singh, A. Duenas-Gonzalez, F. Lyko, and J.L. Medina-Franco Molecular modeling and molecular dynamics studies of hydralazine with human DNA methyltransferase 1 ChemMedChem 4 2009 792 799
185. J. Yoo, and J.L. Medina-Franco Homology modeling, docking and structure-based pharmacophore of inhibitors of DNA methyltransferase J. Comput. Aided Mol. Des. 25 2011 555 567
186. L. Halby, C. Champion, C. Senamaud-Beaufort, S. Ajjan, T. Drujon, A. Rajavelu, A. Ceccaldi, R. Jurkowska, O. Lequin, W.G. Nelson, A. Guy, A. Jeltsch, D. Guianvarc'h, C. Ferroud, and P.B. Arimondo Rapid synthesis of new DNMT inhibitors derivatives of procainamide ChemBioChem 13 2012 157 165
187. B.H. Lee, S. Yegnasubramanian, X. Lin, and W.G. Nelson Procainamide is a specific inhibitor of DNA methyltransferase 1 J. Biol. Chem. 280 2005 40749 40756
188. S. Castellano, D.F. Kuck, M.F. Viviano, J.F. Yoo, F.F. Lopez-Vallejo, P.F. Conti, L.F. Tamborini, A.F. Pinto, G. Medina-Franco, and G. Sbardella Synthesis and biochemical evaluation of delta(2)-isoxazoline derivatives as DNA methyltransferase 1 inhibitors J. Med. Chem. 54 2011 7663 7677
189. S. Castellano, D. Kuck, M. Sala, E. Novellino, F. Lyko, and G. Sbardella Constrained analogues of procaine as novel small molecule inhibitors of DNA methyltransferase-1 J. Med. Chem. 51 2008 2321 2325
190. O. Hoshino, M. Murakata, and K. Yamada A convenient synthesis of a bromotyrosine derived metabolite, psammaplin A, from psammaplysilla sp Bioorg. Med. Chem. Lett. 2 1992 1561 1562
191. D. Kim, I.S. Lee, J.H. Jung, C.O. Lee, and S.U. Choi Psammaplin A, a natural phenolic compound, has inhibitory effect on human topoisomerase II and is cytotoxic to cancer cells Anticancer Res. 19 1999 4085 4090
192. D. Kim, I.S. Lee, J.H. Jung, and S.I. Yang Psammaplin A, a natural bromotyrosine derivative from a sponge, possesses the antibacterial activity against methicillin-resistant Staphylococcus aureus and the DNA gyrase-inhibitory activity Arch. Pharm. Res. 22 1999 25 29
193. J. Shin, H.S. Lee, Y. Seo, J.R. Rho, K.W. Cho, and V.J. Paul New bromotyrosine metabolites from the sponge Aplysinella rhax Tetrahedron 56 2000 9071 9077
194. I.C. Pina, J.T. Gautschi, G.Y. Wang, M.L. Sanders, F.J. Schmitz, D. France, S. Cornell-Kennon, L.C. Sambucetti, S.W. Remiszewski, L.B. Perez, K.W. Bair, and P. Crews Psammaplins from the sponge Pseudoceratina purpurea: inhibition of both histone deacetylase and DNA methyltransferase J. Org. Chem. 68 2003 3866 3873
195. A.M. Godert, N. Angelino, A. Woloszynska-Read, S.R. Morey, S.R. James, A.R. Karpf, and J.R. Sufrin An improved synthesis of psammaplin A Bioorg. Med. Chem. Lett. 16 2006 3330 3333
196. M.G. Baud, T. Leiser, P. Haus, S. Samlal, A.C. Wong, R.J. Wood, V. Petrucci, M. Gunaratnam, S.M. Hughes, L. Buluwela, F. Turlais, S. Neidle, F.J. Meyer-Almes, A.J. White, and M.J. Fuchter Defining the mechanism of action and enzymatic selectivity of psammaplin A against its epigenetic targets J. Med. Chem. 2012
197. J. Garcia, G. Franci, R. Pereira, R. Benedetti, A. Nebbioso, F. Rodriguez-Barrios, H. Gronemeyer, L. Altucci, and A.R. de Lera Epigenetic profiling of the antitumor natural product psammaplin A and its analogues Bioorg. Med. Chem. 19 2011 3637 3649
198. D.H. Kim, J.F. Shin, and H.J. Kwon Psammaplin A is a natural prodrug that inhibits class I histone deacetylase Exp. Mol. Med. 39 2007 47 55
199. H. Tanaka, H. Marumo, T. Nagai, M. Okada, and K. Taniguchi Nanaomycins, new antibiotics produced by a strain of Streptomyces. III. A new component, nanaomycin C, and biological activities of nanaomycin derivatives J. Antibiot. (Tokyo) 28 1975 925 930
200. D. Kuck, N. Singh, F. Lyko, and J.L. Medina-Franco Novel and selective DNA methyltransferase inhibitors: docking-based virtual screening and experimental evaluation Bioorg. Med. Chem. 18 2010 822 829
201. D. Kuck, T. Caulfield, F. Lyko, and J.L. Medina-Franco Nanaomycin A selectively inhibits DNMT3B and reactivates silenced tumor suppressor genes in human cancer cells Mol. Cancer Ther. 9 2010 3015 3023
202. T. Caulfield, and J.L. Medina-Franco Molecular dynamics simulations of human DNA methyltransferase 3B with selective inhibitor nanaomycin A J. Struct. Biol. 176 2011 185 191
203. Z. Liu, Z. Xie, W. Jones, R.E. Pavlovicz, S. Liu, J. Yu, P.K. Li, J. Lin, J.R. Fuchs, G. Marcucci, C. Li, and K.K. Chan Curcumin is a potent DNA hypomethylation agent Bioorg. Med. Chem. Lett. 19 2009 706 709
204. L. Shu, T.O. Khor, J.H. Lee, S.S. Boyanapalli, Y. Huang, T.Y. Wu, C.L. Saw, K.L. Cheung, and A.N. Kong Epigenetic CpG demethylation of the promoter and reactivation of the expression of Neurog1 by curcumin in prostate LNCaP cells AAPS J. 13 2011 606 614
205. E. Burgos-Moron, J.M. Calderon-Montano, J. Salvador, A. Robles, and M. Lopez-Lazaro The dark side of curcumin Int. J. Cancer 126 2010 1771 1775
206. B. Brueckner, B.R. Garcia, P. Siedlecki, T. Musch, H.C. Kliem, P. Zielenkiewicz, S. Suhai, M. Wiessler, and F. Lyko Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases Cancer Res. 65 2005 6305 6311
207. P. Siedlecki, B.R. Garcia, S. Comagic, R. Schirrmacher, M. Wiessler, P. Zielenkiewicz, S. Suhai, and F. Lyko Establishment and functional validation of a structural homology model for human DNA methyltransferase 1 Biochem. Biophys. Res. Commun. 306 2003 558 563
208. T. Suzuki, R. Tanaka, S. Hamada, H. Nakagawa, and N. Miyata Design, synthesis, inhibitory activity, and binding mode study of novel DNA methyltransferase 1 inhibitors Bioorg. Med. Chem. Lett. 20 2010 1124 1127
209. W.A. Denny, G.J. Atwell, B.C. Baguley, and B.F. Cain Potential antitumor agents. 29. Quantitative structure-activity relationships for the antileukemic bisquaternary ammonium heterocycles J. Med. Chem. 22 1979 134 150
210. J. Datta, K. Ghoshal, W.A. Denny, S.A. Gamage, D.G. Brooke, P. Phiasivongsa, S. Redkar, and S.T. Jacob A new class of quinoline-based DNA hypomethylating agents reactivates tumor suppressor genes by blocking DNA methyltransferase 1 activity and inducing its degradation Cancer Res. 69 2009 4277 4285
211. R.J. Amato Inhibition of DNA methylation by antisense oligonucleotide MG98 as cancer therapy Clin. Genitourin. Cancer 5 2007 422 426
212. J. Goffin, and E. Eisenhauer DNA methyltransferase inhibitors-state of the art Ann. Oncol. 13 2002 1699 1716
213. R.B. Klisovic, W. Stock, S. Cataland, M.I. Klisovic, S. Liu, W. Blum, M. Green, O. Odenike, L. Godley, J.V. Burgt, L.E. Van, M. Cullen, A.R. Macleod, J.M. Besterman, G.K. Reid, J.C. Byrd, and G. Marcucci A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemia Clin. Cancer Res. 14 2008 2444 2449
214. J. Flynn, J.Y. Fang, J.A. Mikovits, and N.O. Reich A potent cell-active allosteric inhibitor of murine DNA cytosine C5 methyltransferase J. Biol. Chem. 278 2003 8238 8243
215. A. Reale, G.D. Matteis, G. Galleazzi, M. Zampieri, and P. Caiafa Modulation of DNMT1 activity by ADP-ribose polymers Oncogene 24 2005 13 19
216. R. Goyal, P. Rathert, H. Laser, H. Gowher, and A. Jeltsch Phosphorylation of serine-515 activates the mammalian maintenance methyltransferase Dnmt1 Epigenetics 2 2007 155 160
217. J. Song, M. Teplova, S. Ishibe-Murakami, and D.J. Patel Structure-based mechanistic insights into DNMT1-mediated maintenance DNA methylation Science 335 2012 709 712
218. Z.M. Svedruzic Dnmt1 structure and function Prog. Mol. Biol. Transl. Sci. 101 2011 221 254
219. M. Szyf Epigenetic therapeutics in autoimmune disease Clin. Rev. Allergy Immunol. 39 2010 62 77
220. Y. Boumber, and J.P. Issa Epigenetics in cancer: what's the future? Oncology (Williston. Park) 25 2011 220 226 228
221. S.V. Sharma, D.Y. Lee, B. Li, M.P. Quinlan, F. Takahashi, S. Maheswaran, U. McDermott, N. Azizian, L. Zou, M.A. Fischbach, K.K. Wong, K. Brandstetter, B. Wittner, S. Ramaswamy, M. Classon, and J. Settleman A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations Cell 141 2010 69 80
222. R.L. Momparler, and J. Ayoub Potential of 5-aza-2′-deoxycytidine (decitabine) a potent inhibitor of DNA methylation for therapy of advanced non-small cell lung cancer Lung Cancer 34 Suppl. 4 2001 S111 S115
223. T. Qin, R. Castoro, A.S. El, J. Jelinek, X. Wang, J. Si, J. Shu, R. He, N. Zhang, W. Chung, H.M. Kantarjian, and J.P. Issa Mechanisms of resistance to decitabine in the myelodysplastic syndrome PLoS One 6 2011 e23372
224. V.O. Kaminskyy, O.V. Surova, A. Vaculova, and B. Zhivotovsky Combined inhibition of DNA methyltransferase and histone deacetylase restores caspase-8 expression and sensitizes SCLC cells to TRAIL Carcinogenesis 32 2011 1450 1458
225. L. Simo-Riudalbas, S.A. Melo, and M. Esteller DNMT3B gene amplification predicts resistance to DNA demethylating drugs Genes Chromosomes. Cancer 50 2011 527 534